Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of November 2022, with a filing date of November 4, 2022. The registrant is a foreign private issuer based in Jerusalem, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural announcement regarding corporate governance rather than a financial results report.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this document.
Guidance, Outlook, and Management Commentary
The Company announced the scheduling of an Extraordinary Meeting of Shareholders to be held on December 13, 2022, at 4:00 p.m. Israel time. The meeting will take place at the offices of Gross & Co. in Tel Aviv, Israel. A Notice of the meeting is included as Exhibit 99.1 and incorporated by reference into the Company's Registration Statements on Forms F-3, F-1, and S-8.
Investor Verification Checklist
- Verify the specific agenda items for the Extraordinary Meeting of Shareholders scheduled for December 13, 2022, by reviewing Exhibit 99.1.
- Confirm the record date for shareholder eligibility, which is not stated in this summary text.
- Check subsequent filings for the outcomes of the shareholder vote.
- Note the discrepancy between the requested company name (Scinai Immunotherapeutics Ltd.) and the actual registrant (BiondVax Pharmaceuticals Ltd.).